Adam Simmons, director of clinical program management, Alkermes, explains that an investigational antipsychotic drug, ALKS 3831, provides the efficacy of olanzapine without the associated weight gain can provide benefits in the short and long term to payers and patients. Simmons spoke about data presented at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.
Adam Simmons, director of clinical program management, Alkermes, explains that an investigational antipsychotic drug, ALKS 3831, that provides the efficacy of olanzapine without the associated weight gain can provide benefits in the short and long term to payers and patients.
Transcript
What’s the potential value of ALKS 3831 to payers and patients?
What we’re doing here in presenting the data at APA is specifically getting this out to physicians, talking about it with patients, and in the upcoming months we’ll be able to get some more information specifically about what the value is to payers. I can say in terms of potential value that there’s probably 2 areas that this medication’s going to be valuable, at least to patients and providers.
One, in the short term, we know that for people with schizophrenia it’s a lifelong disease and that in order for them to do well with their maintenance medications they need to stay on their medications, so that if we’ve been able to take a medication that’s already effective and that people sometimes come off of it because of weight gain, if they’re more likely to stay on their medications they’re more likely to stay out of the hospitals and all of the other bad things that happen when patients stop taking their medications, increased risk for suicide, et cetera.
The other long-term value, of course, is that we know that a lot of people stay on olanzapine despite the weight gain, and that longtime, lifelong exposure of higher weight gain is likely to cause a lot of other comorbidities: cardiovascular disease, type 2 diabetes, et cetera. So we think that there’s a value both from the short term, in terms of people staying on their medication and doing well as a maintenance therapy, as well as long term, in not developing comorbidities.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More